Delivery Order SPE2DB22D1106-SPE2DB25FFDK8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of HAVRIX 1,440 Unit/ML Syringe vaccines valued at $1,339.10. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The order is scheduled for completion by August 7, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,490.36 to AmerisourceBergen Drug Corp for the supply of HAVRIX 1,440 Unit/ML vaccine syringes. This competitively awarded, firm fixed-price delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for 1,440 units/mL of Havrix vaccine in syringe form, with a ceiling value of $1,234.12. This is a firm fixed-price delivery order with no set-aside designation, executed competitively, and scheduled for completion by September 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,136.36 for 1,440 units/mL of HAVRIX vaccine syringes on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single transaction under the company's larger pharmaceutical supply relationship...
- The Defense Logistics Agency (DLA) awarded a $1,417.08 delivery order to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes, with an ultimate completion date of July 14, 2025. This firm fixed-price contract, awarded on July 11, 2025, is non-set-aside and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a $1,619.52 delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of HAVRIX 720 Unit/0.5 ML syringes. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, with an...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of HAVRIX 1,440 Unit/ML syringe vaccine. This firm fixed-price, non-set-aside delivery order has a ceiling value of $8,069.00 and an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,597.88 to AmerisourceBergen Drug Corp for 1,440 units/mL of Havrix vaccine in syringes. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes a firm fixed price structure with no set-aside designation. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,828.20 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes. The contract is a firm fixed price delivery order with no set-aside designation, awarded on May 27, 2025, with an ultimate completion date of May 28, 2025. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for 1,440 units of Havrix 1-unit/mL vaccine syringes, valued at $6,200.90 under a firm fixed-price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 billion through December 2026. The contract was competitively awarded with no set-aside...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDK8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of HAVRIX 1,440 Unit/mL vaccine syringes, with a ceiling value of $8,148.75. This is a firm fixed price delivery order with no set-aside designation, placing performance in Conshohocken, Pennsylvania, and scheduled for completion by August 15, 2025. The award represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement extending through December 2026 that authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. As a leading supplier through the DLA Medical Supply Chain, the company maintains a broad portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This specific delivery order for HAVRIX vaccine aligns with the company's established role as a key provider of immunological products and medical commodities supporting military readiness and healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 8/14/25 |